Clariant’s fine chemicals business has begun $12 million in plant expansions at four sites in the U.S. and Europe. The Switzerland-based company says the expansions are “in response to enhanced business opportunities in both its custom manufacturing and generic businesses.” Its investment of $8 million in its Springfield, MO, site is the largest of the expansions and will support production of a current good manufacturing practice antiviral intermediate. Clariant’s $1 million investment in its Sandycroft, UK, site will support the manufacture of a generic active pharmaceutical ingredient. Its investments in two sites in Germany will support development of a regulatory-starting material for a central nervous system application.
Clariant Announces Expansions
Mon, 03/20/2006 - 6:48am